Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|February 29, 2012
An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancerJohnna D Wesley, James Whitmore, James Trager, et al.Plos Pathogens|July 19, 2008
NK cell-like behavior of Valpha14i NK T cells during MCMV infectionJohnna D Wesley, Marlowe S Tessmer, Deanna Chaukos, et al.Clinical Immunology (Orlando, Fla.)|July 1, 2015
Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for successNiels V Rekers, Matthias G von Herrath, Johnna D WesleyFrontiers in Immunology|August 23, 2021
Overcoming Obstacles in the Development of Antigen-Specific Immunotherapies for Type 1 DiabetesRanjeny Thomas, José M Carballido, Johnna D Wesley, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2007
A Y chromosome-linked factor impairs NK T developmentJohnna D Wesley, Marlowe S Tessmer, Christophe Paget, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2005
Cutting edge: IFN-gamma signaling to macrophages is required for optimal Valpha14i NK T/NK cell cross-talkJohnna D Wesley, Scott H Robbins, Stéphane Sidobre, et al.Human Vaccines & Immunotherapeutics|October 30, 2013
Non-antigenic and antigenic interventions in type 1 diabetesAnna K E Rydén, Johnna D Wesley, Ken T Coppieters, et al.Current Opinion in Endocrinology, Diabetes, and Obesity|July 1, 2022
Induction of antigenic immune tolerance to delay type 1 diabetes - challenges for clinical translationJohnna D Wesley, Philippe P Pagni, Regine Bergholdt, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 22, 2010
Cellular requirements for diabetes induction in DO11.10xRIPmOVA miceJohnna D Wesley, Blythe D Sather, Nikole R Perdue, et al.BMC Immunology|March 23, 2018
Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modificationsJohn Sidney, Jose Luis Vela, Dave Friedrich, et al.Pageof 3